Skip to content

Biochemical Pregnancy Loss. A Multicenter Retrospective Study

Is Biochemical Pregnancy Loss Associated to Embryo or Endometrium? A Multicenter Retrospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04549909
Acronym
BPL
Enrollment
20000
Registered
2020-09-16
Start date
2019-02-12
Completion date
2020-01-15
Last updated
2020-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy Loss, Early

Keywords

pregnancy, abortion, bioquemical

Brief summary

Biochemical pregnancy loss (BPL) is a very frequent issue in human reproduction. After the implantation of the embryo, hCG disappears very soon from the maternal bloodstream and no evidence of a clinical pregnancy is seen. Different studies showed that factors such as age, oocyte and embryo quality, and endometrium receptivity may have something to do with the occurrence of biochemical pregnancy loss post assisted reproduction treatment. The main aim of this study is to evaluate the incidence of biochemical pregnancy loss (BPL) in three different cohort populations; patients undergoing frozen embryo transfer (FET) from own oocytes after preimplantation genetic testing for aneuploidy (PGT-A), patients undergoing FET from own and donated oocytes and with endometrial receptivity array (ERA), and patients undergoing FET from own or donated oocytes (without PGTA or ERA test). We will analyse the incidence of BPL in these populations and try to determine the role of the euploid status embryo in the first group, the endometrium in the second group and the third one as control group. We are waiting to find the value of both players in the origin of BPL.

Detailed description

Human embryo implantation is a poorly understood process. Once the embryo implants in the endometrium, it starts to secrete hCG that can be measured in the maternal blood as early as 9 days after implantation. Only a minimal number of pregnancies get to newborn, and the majority are lost before reach the first trimester (Larsen et al., 2013). We are looking for the role of the embryo after controlling its chromosomal ploidy, and the endometrium after controlling its transcriptomic expression. We will also use a no exposed group to the controlled euploid embryo factor neither endometrial factor that is the oocyte donation group. This analysis expects to provide more information about the key role of embryo or endometrium in BPL.

Interventions

Analyse the incidence of BPL in these populations

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
CollaboratorOTHER
IVI Madrid
CollaboratorOTHER
Fundación IVI
CollaboratorOTHER
IVI Vigo
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
No

Inclusion criteria

Patients with the following selection criteria: * IVF/ICSI patients aged between 18 and 44 * BMI 18-30 kg/m2 * Frozen embryo transfer from own oocytes after PGT-A * Frozen embryo transfer with ERA test (from own or donated oocytes) * Frozen embryo transfer (from own or donated oocytes) * Single embryo transfer (SET) in all cycles * Patients without uterine malformations * Patients without recurrent miscarriage (≥ 3) * Patients with adequate endometrial thickness (\> 7mm) * Patients without thyroid autoimmunity * Patients without thrombophilia * Exclude cycles with exclusively PGT-M * Exclude FET in ovarian stimulated cycles

Exclusion criteria

Exclude cycles with exclusively PGT-M Exclude FET in ovarian stimulated cycles \-

Design outcomes

Primary

MeasureTime frameDescription
Biochemical pregnancy loss (BPL)Since 2013 to april 2019when the maternal serum levels of β-hCG are higher than 10 UI/L, but in the transvaginal ultrasound is not possible to appreciate any gestational structure (dichotomous qualitative variable: yes/no). This variable is considered as the fraction between patients whose β-hCG is higher than 10 UI/L, without clinically recognized pregnancy, by number of pregnant patients.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026